Poly Medicure Secures EU MDR Certification for 54 Medical Devices

Medical consumables company Poly Medicure Ltd announced on Tuesday (March 11) that it has received Medical Device Regulation (MDR) certification for 54 of its products.

The certification signifies compliance with the European Union’s strict safety, quality, and regulatory standards, reinforcing the company’s commitment to high-quality healthcare solutions.

Certified Devices Across Multiple Specialties

The 54 certified medical devices cater to a wide range of medical specialities, including:

• Infusion Therapy
• Vascular Access
• Renal Care
• Urology
• Surgery & Wound Care
• Transfusion Systems
• Anaesthesia & Respiratory Care
• Gastroenterology
• Diagnostics

This regulatory approval strengthens Poly Medicure’s position in the global medical consumables market and paves the way for broader adoption of its products across European healthcare institutions.

Commitment to Safety and Quality

Commenting on the achievement, Rishi Baid, Joint Managing Director of Poly Medicure, stated:
“Polymed has been the largest exporter of consumable medical devices for over a decade now. The MDR certification demonstrates that our products not only meet but exceed the most stringent safety and quality standards. We are steadfast in our commitment to these principles, which are at the core of our growth and success.”

Boosting Presence in the European Market

With Europe already contributing 50% of Poly Medicure’s export revenue, this certification will further solidify the company’s standing in the European medical device market. Baid emphasized that the certification would enhance Poly Medicure’s reputation, ensuring greater market penetration and customer trust.

“This certification is a testament to our focus on quality, innovation, and customer satisfaction. It will further strengthen our presence and reputation in the European market,” Baid added.

Strategic Growth and Future Prospects

Securing MDR certification is a significant step forward for Poly Medicure as it looks to expand its footprint in global markets. The recognition not only opens doors to increased sales in Europe but also enhances the company’s credibility in other regulated markets, positioning it for sustained long-term growth.

Stock Performance 

On March 12, 2025, Poly Medicure share price traded 0.05% higher at ₹2,208.95 at 10:39 AM (IST). Poly Medicure’s share price reached a 52-week high of ₹3,350, and a 52-week low of ₹1,373.35. As per BSE, the total traded volume for the stock stood at 3687 shares with a turnover of ₹80.04 lakhs.

At the current price, Poly Medicure shares are trading at a price-to-earnings (P/E) ratio of 71x, based on its trailing 12-month earnings per share (EPS) of ₹31.11, and a price-to-book (P/B) ratio of 8.69, according to exchange data.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.